Our Roots
Alloferon, Allostatin, and FLIP7 were invented by Professor Sergey I. Chernish, a world-renowned expert in the area of immune systems of insects, a member of the Russian academy of sciences. Professor Chernysh has a PhD degree from the St. Petersburg State university (Doctor of biological sciences), was an active Professor in the State University of St. Petersburg, Russia, a scientific vice-director of the Biological Institute of St. Petersburg State University and a head of the Entomology laboratory of St. Petersburg State University.
A life dedicated to fighting cancers and infections
Early in his career, Professor Chernysh realized that the human immune system does not include mechanisms for protection against diseases such as cancers, viral infections, bacterial infections and in particular antibiotic resistant bacterial infections. In his early research, he managed to prove that such mechanisms do exist and can be found in some forms of insects. For example, maggots are strongly attracted odors such as ammonia, resulting from urine or fecal contamination, and fly to areas heavily infected by bacteria. This indicated that their immune systems contain strong mechanism for protection against bacterial and viral infections and other pathogens.
Professor Chernysh continued his work and dedicated his life in pursuit of discovering new medicinal substances and prototypes based on insect immune systems with antiviral, anti-tumor, and antibacterial actions, with the idea that once such mechanisms are discovered, they can be used in treatment on humans.
Discoveries
This life-lasting pursuit of Professor Chernish and over 15 published scientific publications lead to discovery of two critical substances including Alloferons (Patents RU 2172322; US7462360B2; EP1114829B1), Allostatine (Patents RU 2 267 496; US 8,372,406 B2; EP 1 705 182) and FLIP7 (RU 2 447 896; WO/2018/226119).
Allopharm CO
In order to facilitate further research and development of the new medical substances and prototypes, Professor Chernysh founded a company in St. Petersburg, Russia named Allopharm CO. The main focus of the company was to help Russia by developing the prototypes and the technology that is required for manufacturing of the final products.
Vamos Biotech Co Ltd
To facilitate large scale production, and commercialization at international level, an agreement was made with Professor Chernysh and the management of Vamos Holdings Limited in November 2019 to combine resources and form a partnership company to receive transfer of technology and carry out the commercialization of Allostatin and FLIP7 globally while Allopharm remains a Russian distributor. Such centralized approach would create more efficient business vehicle and business operations.